The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factorα

Naoyasu Ueda, Hiroshi Tsukamoto, Hiroki Mitoma, Masahiro Ayano, Atsushi Tanaka, Shun Ichiro Ohta, Yasushi Inoue, Yojiro Arinobu, Hiroaki Niiro, Koichi Akashi, Takahiko Horiuchi

Research output: Contribution to journalArticlepeer-review

48 Citations (Scopus)


Background: Anti-tumor necrosis factor α (anti-TNF-α) agents have been successfully applied for the treatment of rheumatoid arthritis, Crohn's disease, and other chronic inflammatory diseases. Not only the neutralization of soluble TNF-α but also the effect on transmembrane TNF-α is important mechanisms of action of anti-TNF-α agents. This study investigated the cytotoxic effects of new anti-TNF-α agents, certolizumab pegol and golimumab, which are mediated by transmembrane TNF-α. Methods: Transmembrane TNF-α-expressing Jurkat T cells that did not express TNF receptors were used. The binding ability of each anti-TNF-α agent to transmembrane TNF-α, antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity, and the apoptotic effect were examined. Results: Certolizumab pegol and golimumab bound to transmembrane TNF-α. Golimumab induced antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity, which was comparable to infliximab and adalimumab. However, certolizumab pegol did not induce antibody-dependent cell-mediated cytotoxicity or complement-dependent cytotoxicity. Certolizumab pegol directly induced nonapoptotic cell death in transmembrane TNF-α-expressing cells. Golimumab induced a weaker apoptotic effect than infliximab and adalimumab. Conclusions: The cytotoxic effects of anti-TNF-α agents on TNF-α-expressing cells are considered to be associated with the clinical effect of these agents on granulomatous diseases. The direct cytotoxic effect of certolizumab pegol on TNF-α-producing cells may contribute to its clinical efficacy in Crohn's disease. Golimumab may be less effective for granulomatous diseases.

Original languageEnglish
Pages (from-to)1224-1231
Number of pages8
JournalInflammatory bowel diseases
Issue number6
Publication statusPublished - May 2013

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Gastroenterology


Dive into the research topics of 'The cytotoxic effects of certolizumab pegol and golimumab mediated by transmembrane tumor necrosis factorα'. Together they form a unique fingerprint.

Cite this